Joke van Bemmel is the Data, Digital & AI Lead at Genmab, specializing in research and discovery. With a PhD from Erasmus University Rotterdam, her work focuses on leveraging AI and machine learning for antibody design. She holds certifications in immuno-oncology and pharmacology from Harvard Medical School, underscoring her commitment to innovation in drug development.
Outside of her core role, Joke is deeply invested in continuous professional development. She actively pursues advanced knowledge, having completed courses in digital intelligence from Harvard Business Publishing and prompt engineering from the Project Management Institute. Her interests lie at the intersection of cutting-edge science and strategic application.
As a PhD student in 2011, she accurately predicted that the future of medical research would be the combination of lab work and big data sets.
Read the full overview →It is very likely that they will negotiate pricing or other important terms. They like to take decisions independently and do not seek others' support often. Unless the value is proven by data, they are unlikely to value fancy features.
Calculativeness (C) reflects the degree to which a person is likely to be cautious, systematic and analytical. Those scoring high tend to emphasise quality and accuracy.
Explore more public profiles from related professionals.
Discover additional public profiles from our index.
Looking for someone else? Search here for anyone.